Rescue NET for lupus patients

May 03, 2010
This is a scanning electron microscopy image of white blood cells and NETs in a healthy person. Credit: Volker Brinkmann

Lupus is a disease where the immune system attacks healthy cells of the body. This leads to progressive damage of different tissues and organs. The classical characteristic of the disease is the so-called butterfly rash in the face. Many Lupus patients eventually die of kidney failure. Scientists at the Max Planck Institute for Infection Biology in Berlin together with medical scientists from the University of Erlangen succeeded in elucidating basic principles of the disease. This opens up new perspectives for methods that might enable early diagnosis and treatment of Lupus patients with a high risk at kidney failure.

Lupus is one of the most common . The symptoms vary from patient to patient and can include rashes, muscle and joint pain, fatigue, inflammation, and miscarriage. One third of the patients die of kidney failure. Little is known about the origin and the pathogenesis of this disease. Diagnosis is difficult because many symptoms are common with other diseases. The hallmark of is that the body produces antibodies against its own DNA, certain proteins of the nucleus and of white blood cells. The course of the disease is characterized by flares which are often triggered by infections. After a flare the health of the patient improves but often there are sequelae, resulting in a continuous exacerbation of the disease.

Scientists of the Max Planck Institute for Infection Biology suspected that an immune mechanism that was only recently discovered by them, plays a key role in Lupus: During an infection, white blood cells are stimulated and extrude nets in which they trap and kill pathogens (fig. 1). This NET (an acronym for Neutrophil Extracellular Traps) is composed of exactly those components against which a Lupus patient produces antibodies: DNA, as well as proteins of the nucleus and the (fig. 2). In co-operation with clinical scientists from the University of Erlangen, the Max Planck scientists could show for the first time that, in contrast to healthy persons, a part of the Lupus patients could not degrade NETs after the infection.

These are white blood cells and NETs in a lupus patient. The DNA in NETs is shown in blue; the antibodies binding to the NET are shown in red (fluorescence microscopy). Credit: Volker Brinkmann

The scientists also discovered that NETs are degraded by the enzyme DNase-1, a protein which normally is found in the blood. Lupus patients, however, either lack this enzyme or their DNase-1 is blocked. Further examination of this patient group revealed that the remains of NETs together with the auto-antibodies are deposited in the kidneys of SLE patients. Indeed, the scientists showed a strong correlation between the inability to degrade NETs in Lupus and a high risk of . These results provide a starting point for the development of a test that might allow an early diagnosis and treatment of these high risk patients.

Explore further: A real-time tracking system developed to monitor dangerous bacteria inside the body

More information: "Impairment of NET degradation is associated with Lupus nephritis", PNAS, May 3, 2010

add to favorites email to friend print save as pdf

Related Stories

Researchers pioneer kidney disease prediction method

Nov 05, 2009

(PhysOrg.com) -- A study into the relationship between antibodies and proteins in people with Lupus could mean earlier diagnosis of kidney disease in such patients, and lead the way for earlier diagnoses for ...

Kidney transplants generally safe for lupus patients

Nov 02, 2009

Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology's ...

Lupus gene finding prompts call for more DNA samples

Dec 02, 2007

Wellcome Trust researchers have identified a key gene involved in the disease Lupus, which affects around 50,000 people in the UK, mostly women. The lead researcher behind the study has called for more patients to volunteer ...

Rituximab reduces kidney inflammation in patients with lupus

Mar 04, 2009

Treatment with the targeted drug rituximab can significantly benefit some patients with severe lupus nephritis who do not respond to conventional therapy, according to a study appearing in an upcoming issue of the Clinical Jo ...

Recommended for you

Cause of ageing remains elusive

15 hours ago

A report by Chinese researchers in the journal Nature a few months ago was a small sensation: they appeared to have found the cause for why organisms age. An international team of scientists, headed by the ...

Newly discovered bacterial defence mechanism in the lungs

16 hours ago

A new study from Karolinska Institutet presents a previously unknown immunological mechanism that protects us against bacterial infections in the lungs. The study is being published in the American Journal of Respiratory an ...

User comments : 4

Adjust slider to filter visible comments by rank

Display comments: newest first

Au-Pu
not rated yet May 03, 2010
Brilliant.
This may be the beginning of understanding the cause of all autoimmune diseases.
The probability must be high that they are all caused by similar processes
fixer
not rated yet May 03, 2010
Interesting reading, but no solution offered!
The A.R.F. has this subject well in hand with clinical trials well completed and therapy available worldwide.
Here is a quick link for health proffesionals and patients- http://www.youtub...Marshall

Sorry Max Planck, you missed the boat by several years!
ChiRaven
not rated yet May 03, 2010
I wonder how Marshall's "VDR knockout" procedure (which is, apparently, purely an observed phenomenon, with no ascribed subcellular mechanism presented ... at least in his brief synopsis) would be supported by this NET phenomenon? In other words, could the NET phenomenon be a CAUSE of VDR knockout?
fixer
not rated yet May 03, 2010
To get a meaningful answer to that question go here- http://www.curemyth1.org/